JBJI Journal of Bone and Joint Infection JBJI J. Bone Joint Infect. 2206-3552 Ivyspring Göttingen, Germany 10.7150/jbji.30029 Rifampin-Resistant <em>Cutibacterium</em> (formerly <em>Propionibacterium</em>) <em>namnetense</em> Superinfection after <em>Staphylococcus aureus</em> Bone Infection Treatment Corvec Stéphane 1 2 3 Guillouzouic Aurélie 1 Aubin Guillaume Ghislain 1 Touchais Sophie 3 4 Grossi Olivier 3 5 Gouin François 3 4 Bémer Pascale 1 3 Service de Bactériologie-Hygiène hospitalière, CHU de Nantes, Nantes, France CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France Nantes study group member of CRIOGO (Centre de Référence des Infections Ostéo-articulaires du Grand Ouest), Nantes, France Clinique chirurgicale orthopédique et traumatique, CHU de Nantes, Nantes, France. Service de Maladies infectieuses, CHU de Nantes, Nantes, France - Département de Médecine Interne -Infectiologie, Nouvelles Cliniques Nantaises, Nantes, France 24 11 2018 3 5 255 257 Copyright: © 2018 Stéphane Corvec et al. 2018 This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/ This article is available from https://jbji.copernicus.org/articles/3/255/2018/jbji-3-255-2018.html The full text article is available as a PDF file from https://jbji.copernicus.org/articles/3/255/2018/jbji-3-255-2018.pdf

<p class="p p-first-last" id="__p2">After rifampin and levofloxacin treatment for a <em>Staphylococcus aureus</em> bone infection, a pyogenic granuloma due to a newly described <em>Cutibacterium</em> species,<em> C. namnetense</em> developed on the tibia former external fixator. This rifampin resistant bacterium, selected during treatment, harbored a mutation in the <em>rpoB</em> gene. This case illustrates the possible <em>in vivo</em> selection of resistant mutant most likely due to the bacterial burden and therefore the importance of adequate bone infection treatment.</p>

 References Aubin GG, Lavigne JP, Guyomarch B. et al. Staphylokinase and ABO group phenotype:new players in Staphylococcus aureus implant-associated infection development. Future Microbiol. 2015;10:1929–1938. Aubin GG, Bémer P, Guillouzouic A. et al. Failure of combination therapy for Staphylococcus aureus bone infection: a case of in vivo selection with resistance to rifampicin and fusidic acid. Infect Dis Lond Engl. 2016;48:699–702. Aubin GG, Portillo ME, Trampuz A. et al. Propionibacterium acnes, an emerging pathogen: From acne to implant-infections, from phylotype to resistance. Med Mal Infect. 2014;44:241–250. Portillo ME, Corvec S, Borens O, Propionibacterium acnes: an underestimated pathogen in implant-associated infections. BioMed Res Int; 2013. p. 804391. [PMC free article] Aubin GG, Bémer P, Kambarev S. et al. Propionibacterium namnetense sp. nov, isolated from a human bone infection. Int J Syst Evol Microbiol. 2016;66:3393–3399. Aubin GG, Kambarev S, Bémer P, Draft Genome Sequence of Highly Rifampin-Resistant Propionibacterium namnetense NTS 31307302T Isolated from a Patient with a Bone Infection. Genome Announc; 2016. p. 11. 4. [PMC free article] Furustrand Tafin U, Aubin GG, Eich G, Occurrence and new mutations involved in rifampicin-resistant Propionibacterium acnes strains isolated from biofilm or device-related infections. Anaerobe; 2015. p. 34. 116-119. Osmon DR, Berbari EF, Berendt AR. et al. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2013;56:e1–e25. Aubry-Damon H, Soussy CJ, Courvalin P. Characterization of mutations in the rpoB gene that confer rifampin resistance in Staphylococcus aureus. Antimicrob Agents Chemother. 1998;42:2590–2594. [PMC free article] Furustrand Tafin U, Trampuz A, Corvec S. In vitro emergence of rifampicin resistance in Propionibacterium acnes and molecular characterization of mutations in the rpoB gene. J Antimicrob Chemother. 2013;68:523–528. Drancourt M, Stein A, Argenson JN. et al. Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin. J Antimicrob Chemother. 1997;39:235–240.